Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Ulmus Americana Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of Type I hypersensitivity to American Elm tree pollen through skin testing and subcutaneous immunotherapy.
Name
Ulmus Americana Pollen
Raw Name
ULMUS AMERICANA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
24
Variant Count
26
Last Verified
February 17, 2026
About Ulmus Americana Pollen
Ulmus Americana Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of Type I hypersensitivity to American Elm tree pollen through skin testing and subcutaneous immunotherapy.
Detailed information about Ulmus Americana Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Ulmus Americana Pollen.
Ulmus Americana Pollen, commonly known as American Elm pollen, is a biological substance utilized in the field of allergology for both diagnostic and therapeutic purposes. It belongs to the pharmacological class known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are complex mixtures of proteins, glycoproteins, and polysaccharides derived from the male reproductive spores of the Ulmus americana tree, a species native to eastern North America. In clinical practice, this extract is utilized by healthcare providers to identify individuals with allergic rhinitis (hay fever), allergic conjunctivitis (eye allergies), or seasonal asthma triggered by elm tree pollen.
According to the FDA-approved labeling for allergenic extracts, these products are indicated for the skin test diagnosis of patients with a history of allergy to specific substances and for the treatment of those patients as immunotherapy (allergy shots). The American Elm is a significant contributor to spring pollinosis (seasonal allergies caused by pollen). Because it is a 'non-standardized' extract, its potency is typically expressed in terms of Protein Nitrogen Units (PNU) or weight/volume (w/v) ratios, rather than bioequivalent allergy units (BAU), which distinguishes it from standardized extracts like those for certain grasses or dust mites.
The mechanism of action for Ulmus Americana Pollen involves two distinct phases: the diagnostic phase and the therapeutic phase. At the molecular level, the extract contains specific allergens (antigens) that interact with the patient's immune system.
In the diagnostic phase (skin testing), the extract is introduced into the epidermis (the outermost layer of skin). If a patient is sensitized, IgE antibodies (immunoglobulin E) bound to the surface of mast cells in the skin recognize the elm pollen proteins. This recognition triggers 'degranulation,' a process where mast cells release inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a 'wheal and flare' reaction—a raised, itchy bump surrounded by redness—which confirms the patient's sensitivity to American Elm.
In the therapeutic phase (immunotherapy), the healthcare provider administers gradually increasing doses of the extract via subcutaneous injection. This process, known as desensitization or hyposensitization, aims to shift the immune response from a Th2-dominated profile (associated with allergy and IgE production) to a Th1-dominated profile or a regulatory T-cell (Treg) response. Over time, this leads to the production of 'blocking antibodies' known as IgG4 (immunoglobulin G4). These antibodies intercept the pollen allergens before they can bind to IgE on mast cells, thereby reducing the allergic symptoms during natural exposure to elm trees.
Traditional pharmacokinetic studies (absorption, distribution, metabolism, and excretion) are not typically conducted for allergenic extracts like Ulmus Americana Pollen because they are not intended to reach systemic circulation in the same manner as oral or intravenous drugs.
Ulmus Americana Pollen is primarily indicated for:
Ulmus Americana Pollen is available in the following formats:
> Important: Only your healthcare provider can determine if Ulmus Americana Pollen is right for your specific condition.
Dosage for Ulmus Americana Pollen is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels.
Ulmus Americana Pollen is used in children, but the safety and efficacy have not been established in very young children (typically under age 5) due to the difficulty of cooperation and the risk of systemic reactions. When used in older children, the dosing schedule is generally similar to that of adults but may require more cautious increments. Healthcare providers must carefully monitor pediatric patients for any signs of distress or systemic reaction.
No specific dose adjustments are required for patients with renal impairment, as the extract is not cleared via the kidneys in a manner that would affect its safety profile. However, the patient's overall health should be considered.
No dose adjustments are necessary for hepatic impairment. The metabolic breakdown of the proteins occurs locally and via general protein catabolism.
Elderly patients (over 65) should be evaluated for cardiovascular health before starting immunotherapy. If an elderly patient has significant heart disease, they may be at higher risk if a systemic reaction (anaphylaxis) occurs, as their body may not tolerate the physiological stress or the epinephrine used for treatment.
Ulmus Americana Pollen extracts are never for self-administration. They must be administered by a trained healthcare professional in a clinical setting equipped to handle emergency allergic reactions.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If the delay is more than 1-2 weeks, the allergist will follow a specific 'missed dose protocol' to ensure safety. During the maintenance phase, a delay of several weeks may require a temporary reduction in the dose to prevent a systemic reaction upon resumption.
An overdose in the context of allergenic extracts refers to the administration of a dose higher than the patient's current tolerance level. This can lead to severe local reactions (large swelling) or systemic reactions (anaphylaxis). Immediate emergency measures include the administration of epinephrine (1:1000), antihistamines, and potentially corticosteroids or oxygen. Healthcare providers must have an emergency kit ready at all times.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing immunotherapy with Ulmus Americana Pollen will experience local reactions at the site of injection. These are generally considered a normal part of the immune response.
> Warning: Stop taking Ulmus Americana Pollen and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' side effects of Ulmus Americana Pollen extract. The primary long-term effect is the desired 'immunological tolerance,' where the body no longer reacts to elm pollen. However, if a patient is improperly dosed over a long period, they may experience chronic localized inflammation at the injection sites. There is no evidence that allergenic extracts cause cancer, autoimmune diseases, or organ damage when used as directed.
Allergenic extracts, including Ulmus Americana Pollen, carry a significant warning regarding the risk of anaphylaxis.
Report any unusual symptoms to your healthcare provider.
Ulmus Americana Pollen is a potent biological product. Safety is dependent on accurate skin testing, precise dose escalation, and strict adherence to administration protocols. Patients must be aware that even if they have tolerated previous injections well, the risk of a systemic reaction is always present. Factors such as exercise, heat exposure (hot showers), or illness shortly after an injection can increase the rate of absorption and the risk of a reaction.
No FDA black box warnings for Ulmus Americana Pollen specifically, but it falls under the general Boxed Warning for all Allergenic Extracts. The summary of this warning emphasizes that these products are intended for use only by physicians who are exceptionally proficient in the diagnosis and treatment of allergic diseases. The warning highlights that severe systemic reactions can occur and that the facility must be equipped with emergency supplies, including epinephrine, to treat anaphylaxis immediately.
There are no standard laboratory tests (like blood counts or liver enzymes) required for Ulmus Americana Pollen. Instead, monitoring is clinical:
Generally, Ulmus Americana Pollen does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.
There is no direct interaction between alcohol and the extract. However, alcohol can cause vasodilation (widening of blood vessels), which could theoretically increase the rate of allergen absorption. It is generally advised to avoid alcohol for several hours after an injection.
Immunotherapy is typically continued for 3 to 5 years. If the treatment is stopped prematurely, the allergic symptoms may return. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the clinical benefits will gradually diminish over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Ulmus Americana Pollen.
While there are few 'absolute' drug-drug contraindications, the following are critical:
There are no known direct food interactions with Ulmus Americana Pollen. However, patients with 'Oral Allergy Syndrome' (Pollen-Food Allergy Syndrome) may find that their sensitivity to certain fruits or vegetables increases during the elm pollen season or during the build-up phase of immunotherapy. This is due to cross-reactivity between pollen proteins and food proteins.
There is limited data on herbal interactions. However, any supplement that affects the immune system or blood pressure should be reported to the allergist. For example, supplements with stimulant properties (like ephedra or high-caffeine products) could complicate the management of a systemic reaction.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Ulmus Americana Pollen must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients allergic to American Elm may also show sensitivity to other members of the Ulmaceae family, such as Chinese Elm (Ulmus parvifolia) or Cedar Elm (Ulmus crassifolia). While the extracts are specific, the proteins are similar enough that a patient highly sensitive to one may react to another. There is also minor cross-reactivity noted between Elm and certain other tree pollens in the Urticales order.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ulmus Americana Pollen.
Pregnancy Category C. There are no adequate and well-controlled studies of Ulmus Americana Pollen in pregnant women.
It is not known whether the allergenic components of Ulmus Americana Pollen are excreted in human milk. However, since the allergens are proteins that are degraded locally, it is highly unlikely that they would reach the infant in any significant amount. Immunotherapy is generally considered safe for breastfeeding mothers, but the mother should be monitored for systemic reactions as usual.
Ulmus Americana Pollen is approved for use in children who demonstrate clinical sensitivity.
Use in patients over 65 requires caution. The primary concern is the presence of comorbid conditions such as coronary artery disease or hypertension. Elderly patients are more likely to be on medications like beta-blockers or ACE inhibitors, which complicate the safety of immunotherapy. The physician must ensure the patient's cardiovascular system can handle a potential systemic reaction.
No dosage adjustment is required for patients with renal disease. The proteins in the extract are not cleared by the kidneys in their active form.
No dosage adjustment is required for patients with hepatic disease. The liver does not play a primary role in the immediate processing or clearance of subcutaneous allergenic extracts.
> Important: Special populations require individualized medical assessment.
Ulmus Americana Pollen extract acts as an immunomodulator. In an allergic individual, exposure to elm pollen results in a Type I hypersensitivity reaction mediated by IgE antibodies. The extract works by inducing 'immunological tolerance.'
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous local action) |
| Protein Binding | N/A |
| Half-life | Variable (Proteins degraded within hours/days) |
| Tmax | 15-30 minutes (for local immune interaction) |
| Metabolism | Local Proteolysis |
| Excretion | Minimal renal excretion of metabolites |
Ulmus Americana Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is part of the broader category of biologicals used for allergen-specific immunotherapy. Related medications include other tree pollen extracts (e.g., Oak, Maple, Birch) and standardized extracts like Ragweed or Timothy Grass.
Common questions about Ulmus Americana Pollen
Ulmus Americana Pollen is primarily used by allergists to diagnose and treat allergies to the American Elm tree. In the diagnostic phase, it is used in skin prick tests to see if a patient develops a 'wheal and flare' reaction, confirming an allergy. In the therapeutic phase, it is used in allergen immunotherapy, commonly known as allergy shots. This involves giving the patient gradually increasing amounts of the pollen extract to desensitize their immune system. Over time, this treatment reduces the symptoms of hay fever and allergic asthma triggered by elm trees.
The most common side effects are local reactions at the site of the injection or skin test. These include redness, itching, and swelling, which usually appear within minutes and fade within a few hours. Some patients may experience 'large local reactions' where the swelling is several inches wide. These local symptoms are generally not dangerous but should be reported to the doctor. Systemic symptoms like sneezing or a mild headache can also occur, though they are less frequent than local skin reactions.
It is generally recommended to avoid alcohol for several hours after receiving an injection of Ulmus Americana Pollen. Alcohol causes vasodilation, which is the widening of blood vessels, and this could potentially speed up the absorption of the allergen into your bloodstream. Faster absorption increases the risk of a systemic allergic reaction or anaphylaxis. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as lightheadedness or flushing. Always check with your allergist for their specific policy regarding alcohol and allergy shots.
Ulmus Americana Pollen is classified as Pregnancy Category C, meaning there is limited data on its safety in humans. Most allergists will not start a new course of immunotherapy (the build-up phase) during pregnancy because of the risk of anaphylaxis, which could harm the fetus. However, if a woman is already on a stable maintenance dose and becomes pregnant, many doctors allow her to continue the treatment. The decision is based on a careful balance of the risks of the treatment versus the risks of uncontrolled allergy or asthma symptoms. You must inform your doctor immediately if you become pregnant while receiving these injections.
For diagnostic skin testing, the results are available almost immediately, usually within 15 to 20 minutes. For therapeutic immunotherapy, the process is much slower and requires patience. Most patients do not notice a significant improvement in their allergy symptoms until they reach their maintenance dose, which typically takes 3 to 6 months of weekly injections. Full effectiveness is often not achieved until the patient has been on maintenance for 6 to 12 months. A complete course of treatment usually lasts 3 to 5 years to ensure long-lasting immunity.
Yes, you can stop taking Ulmus Americana Pollen injections suddenly without experiencing any physical withdrawal symptoms, as it is not an addictive medication. However, stopping the treatment before the recommended 3-to-5-year course is finished often results in the return of your allergy symptoms. If you miss several doses due to illness or travel, you should not simply resume at your previous dose; your doctor will need to adjust the dose downward for safety. Always discuss your plans with your allergist before stopping immunotherapy to understand how it might affect your long-term allergy management.
If you miss a dose of Ulmus Americana Pollen during your immunotherapy schedule, you should contact your allergist's office to reschedule as soon as possible. Do not attempt to 'double up' on your next dose. If only a few days have passed, your doctor may give you the scheduled dose. However, if one or more weeks have passed, the doctor will likely need to reduce the dose to ensure your safety, as your sensitivity to the extract may have increased during the break. Safety protocols for missed doses are strictly followed to prevent systemic reactions.
There is no clinical evidence to suggest that Ulmus Americana Pollen extracts cause weight gain. The extract consists of proteins and glycoproteins that work locally and on the immune system; they do not affect metabolism, appetite, or fat storage. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as the use of oral corticosteroids for asthma or changes in lifestyle. If you have concerns about weight changes, you should discuss them with your primary care physician to identify the underlying cause.
Ulmus Americana Pollen can be taken alongside many common medications, but there are some very important exceptions. You must tell your doctor if you are taking beta-blockers, ACE inhibitors, or MAO inhibitors, as these can make allergic reactions more dangerous or harder to treat. Antihistamines and certain antidepressants must be stopped before skin testing because they can cause false-negative results. Most other routine medications for blood pressure, cholesterol, or diabetes do not interact with the pollen extract. Always provide your allergist with a complete list of all medications and supplements you use.
The concept of 'generic' drugs does not apply to allergenic extracts in the same way it does to chemical tablets. Ulmus Americana Pollen is a biological product produced by several different specialized laboratories (such as Greer, HollisterStier, or ALK). While different companies may produce the extract, they are not considered identical or interchangeable because they are 'non-standardized.' This means the exact protein composition can vary between manufacturers. Your allergist will typically stick with one manufacturer's extract for your entire course of treatment to ensure consistent dosing and safety.